Keeley-Teton Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Keeley-Teton Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$609K	Buy	18,598 +4,961	+36%	+$176K	0.07%	267
2024 Q4	$493K	Sell	13,637 -2,163	-14%	-$76.2K	0.06%	291
2024 Q3	$493K	Hold	15,800	–	–	0.05%	308
2024 Q2	$423K	Hold	15,800	–	–	0.05%	293
2024 Q1	$539K	Hold	15,800	–	–	0.07%	272
2023 Q4	$457K	Hold	15,800	–	–	0.06%	285
2023 Q3	$436K	Hold	15,800	–	–	0.06%	276
2023 Q2	$475K	Hold	15,800	–	–	0.06%	284
2023 Q1	$572K	Buy	15,800 +1,400	+10%	+$53.8K	0.07%	276
2022 Q4	$514K	Buy	14,400 +3,400	+31%	+$118K	0.06%	289
2022 Q3	$372K	Hold	11,000	–	–	0.05%	304
2022 Q2	$318K	Hold	11,000	–	–	0.04%	330
2022 Q1	$356K	Buy	+11,000	New	+$337K	0.04%	336

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Keeley-Teton Advisors's SUPN Position: Q1 2025 in Review

Keeley-Teton Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 36% in Q1 2025, buying an estimated $176K and bringing the position to 18,598 shares worth $609K. The position accounts for 0.07% of the portfolio, ranked #267.

Keeley-Teton Advisors first reported a position in SUPN in Q1 2022 and has held it in 13 quarters since. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

Keeley-Teton Advisors held 18,598 shares of Supernus Pharmaceuticals worth $609K as of Q1 2025.
Keeley-Teton Advisors bought 4,961 Supernus Pharmaceuticals shares in Q1 2025, an estimated $176K.
Supernus Pharmaceuticals made up 0.07% of Keeley-Teton Advisors's portfolio in Q1 2025, its #267 holding.
Keeley-Teton Advisors first reported a position in Supernus Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Keeley-Teton Advisors's 13F filing for Q1 2025, filed 14 May 2025.